#Pharmaceutical-Industry Archive

Editorial & Columns

Valuation Premium: India-listed Subsidiaries of Pharma and Healthcare MNCs Outshine Parent firms

June 26, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

ESG Frameworks and Pharmaceutical Industry in India

June 6, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Skin in the Game: Promoter Holding in Indian Pharmaceutical Companies

May 15, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Pharma 2.0: Indian Pharmaceutical Companies strive to Create & Enhance Strength in Biopharmaceuticals

May 2, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Drivers of Business Growth : Evidence from Indian Pharmaceutical Industry

April 18, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Prescription for Segment Reporting by Pharmaceutical Companies in India

April 13, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Foreign Direct Investment and Pharmaceutical Industry in India

April 5, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Third Generation Curse : Caution & Survival Lessons for family-owned Pharmaceutical Companies in India

March 14, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Editorial & Columns

Indian Pharmaceutical Industry’s dependence on China for APIs, KSMs & Intermediates: A Historical Perspective

March 1, 2024 | Dr. Anil Kumar Angrish | No Comments |

More

Contact Us